BioVie Inc. Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months
BioVie Inc. (BIVI) had Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months of $229.38 thousand as of 2023-06-30, per its 10-K filed 2023-08-16.
Discontinued › Notes › Intangible Assets › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Rolling Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths · last filed 2023-08-16
- 2023-06-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $229.38K.
- 2023-03-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $57.34K.
- 2022-12-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $114.69K.
- 2022-09-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $172.03K.
| Period end | Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months | Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months as first filed |
|---|---|---|
| 2023-06-30 | $229.38K 10-K · filed 2023-08-16 | |
| 2023-03-31 | $57.34K 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $114.69K 10-Q · filed 2023-02-10 | |
| 2022-09-30 | $172.03K 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $229.38K 10-K · filed 2022-09-27 | |
| 2022-03-31 | $57.35K 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $114.69K 10-Q · filed 2022-02-08 | |
| 2021-09-30 | $172.03K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $229.38K 10-K · filed 2021-08-30 | |
| 2021-03-31 | $57.34M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $114.69K 10-Q · filed 2021-01-29 | |
| 2020-09-30 | $172.03K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $229.38K 10-K/A · filed 2020-08-07 | |
| 2020-03-31 | $57.34K 10-Q · filed 2020-05-13 | |
| 2019-12-31 | $114.69K 10-Q · filed 2020-02-13 | |
| 2019-09-30 | $172.03K 10-Q · filed 2019-11-19 | |
| 2019-06-30 | $229.38K 10-K · filed 2019-09-27 | |
| 2019-05-10 | $57.34K 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $114.69K 10-Q · filed 2019-02-12 | |
| 2018-06-30 | $172.03K 10-Q · filed 2018-11-14 | $229.38K 10-K · filed 2018-10-05 |
| 2018-03-31 | $57.34K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |